Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 2Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 2Neoplasms 1Cardiovascular Diseases 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hydroxymethylglutaryl-CoA Reductase Inhibitors × Genitourinary × Clear all
NCT03127631 2025-01-31

RADICALPC

McMaster University

Phase NA Recruiting
6,000 enrolled
Genitourinary

Cardiovascular Diseases, Prostatic Neoplasms

NCT00572468 2017-07-13

Statin Therapy Versus Placebo Prior to Prostatectomy

VA Office of Research and Development

Phase NA Completed
42 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡